Applied Radiation Oncology

Mini-Protein Carries Radiation Dose to Tumor Without Harming Healthy Tissues 🔗 https://bit.ly/48rBtvN “This is the first time we are seeing a completely new technology used for targeted radiation. A small protein made to seek out a different protein that many cancers express, Nectin-4, was used to take radiation directly to the tumour,” he said.

Researchers Use $3.3M NCI Grant to Develop Breast CT System 🔗 https://bit.ly/48nPFWk “With our technology, there is a hole on the table and the woman lies prone with the breast through the hole. The tube spins around 360 degrees,” said Srinivasan Vedantham

GE HealthCare Announce AI-Based Cloud-First Application to Bring Together Disparate Oncology Data 🔗 https://bit.ly/3YGyr3a “Tampa General Hospital is looking forward to evaluating CareIntellect for Oncology to provide our care teams with information to move from analysis to action—including making use of the proactive pathways to inform care progression and clinical trial eligibility information,” said Dr. Peter Chang, Senior Vice President, Chief Transformation Officer at Tampa General Hospital. “We were impressed by how quickly GE HealthCare was able to design the application to include breast cancer in a matter of weeks. We look forward to putting this in the hands of our care teams and using the AI-enabled functionality to help clinicians spend time where it matters most—delivering outstanding patient care.”

Planning Target Volume Margin Assessment of Retroperitoneal Tumors Using Robotic SBRT With Spine Tracking 🔗 https://bit.ly/3PPdiPt When treating retroperitoneal tumors with robotic SBRT, a minimum isometric margin expansion of 5 mm when creating the PTV is recommended if spine tracking is used for intrafraction motion assessment. Target volumes adjacent to the vertebral column may have PTV margins decreased to 4 mm without compromise in target coverage.

🔗 https://bit.ly/49g7yFG “It is an explainable AI tool, which means that it shows the reasoning behind its decision-making. This makes it easier not only for doctors to make decisions, but also to provide data-backed explanations to their patients,” said Dr Rattay, who is a consultant breast surgeon and Associate Professor at the Leicester Cancer Research Centre, University of Leicester (UK).

Positive Findings Reported for SECuRE Copper-67 Clinical Trial 🔗 https://bit.ly/4dT7PR2 Clarity Pharmaceuticals shared several updates on the 67Cu-SAR-bisPSMA program. Cohort 4 is anticipated to be the final cohort in the dose escalation phase of the SECuRE study (pending final safety assessment by the Safety Review Committee [SRC]), with participants receiving a minimum of 2 and a maximum of 4 doses of 67Cu-SAR-bisPSMA at 12GBq.

📢 New RadOnc Student Scan! Ethical considerations in the era of AI, interviews with Radiation Oncologists, career development opportunities, upcoming conferences and more! https://bit.ly/3Yyl70V

🔗 https://bit.ly/43wYydL “We know that in young patients, there is a higher chance of the breast cancer returning in the same place following breast-conserving treatment. In this trial we were aiming to lower that risk by giving patients a high radiotherapy boost directed at the site of the tumour. We were also comparing a higher and lower dose to see which one worked best for young patients in terms of local control and cosmetic outcome.”

Case Report: Mediastinal Epithelioid Hemangioendothelioma in a Patient With Concurrent Early Stage Right Breast Cancer 🔗 https://bit.ly/3AgLiQf

Dual Immunotherapy with Chemotherapy Benefits Specific Subgroup of Lung Cancer Patients 🔗 https://bit.ly/48d9BeB "These findings support that NSCLC patients with STK11 or KEAP1 mutations are relatively resistant to standard combinations of PD-(L)1 inhibitors and chemotherapy, but can benefit markedly when a CTLA-4 inhibitor is added to their treatment regimen," said co-lead author John Heymach, MD, PhD, chair of Thoracic/Head and Neck Medical Oncology. "We are optimistic that these results will prompt clinicians to consider this novel therapeutic approach as a preferred treatment option."